Vaxart Inc

NASDAQ: VXRT    
Share price (3/27/24): $1.29    
Market cap (3/27/24): $224 million

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2
from SC 13D 4 pages Lock-Up Agreement
12/34/56
EX-2.2
from 8-K 8 pages Support Agreement
12/34/56
EX-2.2
from 425 8 pages Support Agreement
12/34/56
EX-2.1
from 8-K 3 pages Amendment No. 1 to the Agreement and Plan of Merger and Reorganization
12/34/56
EX-2.1
from 425 3 pages Amendment No. 1 to the Agreement and Plan of Merger and Reorganization
12/34/56
EX-2.4
from S-4/A 6 pages Lock-Up Agreement
12/34/56
EX-2.3
from 425 8 pages Form of Parent Support Agreement
12/34/56
EX-2.3
from 8-K 8 pages Form of Parent Support Agreement
12/34/56
EX-2.2
from 425 9 pages Form of Company Support Agreement
12/34/56
EX-2.2
from 8-K 9 pages Form of Company Support Agreement
12/34/56
EX-2.1
from 8-K 102 pages Agreement and Plan of Merger and Reorganization Among: Aviragen Therapeutics, Inc., a Delaware Corporation; Agora Merger Sub, Inc., a Delaware Corporation; and Vaxart, Inc., a Delaware Corporation Dated as of October 27, 2017
12/34/56
EX-2.1
from 425 102 pages Agreement and Plan of Merger and Reorganization Among: Aviragen Therapeutics, Inc., a Delaware Corporation; Agora Merger Sub, Inc., a Delaware Corporation; and Vaxart, Inc., a Delaware Corporation Dated as of October 27, 2017
12/34/56
EX-2
from SC 13D 2 pages Plan of reorganization, merger, acquisition or similar
12/34/56
EX-2.1
from 10-Q 92 pages Stock Purchase Agreement by and Among Biota Pharmaceuticals, Inc., Each of the Shareholders of Anaconda Pharma Party Hereto, and the Holder Representative Dated as of February 25, 2015
12/34/56
EX-2.1
from 8-K 6 pages September 17, 2012 Biota Holdings Limited (Acn 006 479 081) Unit 10, 585 Blackburn Road Notting Hill, Victoria 3168 (Biota). NABI Biopharmaceuticals 12270 Wilkins Avenue Rockville, Maryland 20852 (NABI). Strictly Confidential Merger Implementation Agreement the Parties to This Deed Refer to the Merger Implement Agreement Between the Parties Dated 22 April 2012 as Amended by the Merger Implementation Agreement Amendment Dated 6 August 2012 (The Mia). the Parties Have Agreed to Amend the Terms of the Mia, With Effect on and From the Date of This Deed, on the Terms Set Out in This Deed. Each Party Will Responsible for Their Own Costs Incurred in Connection With the Changes to the Proposed Merger as Set Out in This Deed. All Capitalised Terms in This Deed Have the Meaning Given to Them in the Mia. a Reference to $ Is a Reference to the Lawful Currency of Australia. a Reference to US$ Is a Reference to the Lawful Currency of the United States. 1. Amendments to Clause 1.1 of the Mia Clause 1.1 of the Mia Is Amended as Follows
12/34/56
EX-2.1
from 8-K 4 pages August 6, 2012 Biota Holdings Limited (Acn 006 479 081) Unit 10, 585 Blackburn Road Notting Hill, Victoria 3168 (Biota). NABI Biopharmaceuticals 12270 Wilkins Avenue Rockville, Maryland 20852 (NABI). Strictly Confidential Merger Implementation Agreement – Amendment the Parties to This Letter Refer to the Merger Implement Agreement Between the Parties Dated 22 April 2012 (The Mia). the Parties Have Agreed to Amend the Terms of the Mia as Set Out in This Letter. All Capitalised Terms in This Letter Have the Meaning Given to Them in the Mia. 1. Amendment to Definition of ‘NABI Charter Amendment’ the Definition of ‘NABI Charter Amendment’ in Clause 1.1 of the Mia Is Deleted and Replaced With the Following
12/34/56
EX-2.1
from 8-K 79 pages Merger Implementation Agreement
12/34/56
EX-2.1
from DEFA14A 79 pages Merger Implementation Agreement
12/34/56
EX-2.1
from 10-Q 60 pages Asset Purchase Agreement by and Between NABI Biopharmaceuticals and Glaxosmithkline Biologicals S.A. Dated as of August 5, 2009
12/34/56
EX-2.1
from 8-K 92 pages Asset Purchase Agreement by and Among NABI Biopharmaceuticals, Biotest Pharmaceuticals Corporation and Biotest AG Dated as of September 11, 2007
12/34/56